The Hyperactivity–Impulsivity–Irritiability–Disinhibition–Aggression–Agitation Domain in Alzheimer’s Disease: Current Management and Future Directions
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Behavioral and psychological symptoms of dementia (BPSD) afflict the vast majority of patients with dementia, especially those with Alzheimer’s Disease (AD). In clinical settings, patients with BPSD most often do not present with just one symptom. Rather, clusters of symptoms commonly co-occur and can thus be grouped into behavioral domains that may ultimately be the result of disruptions in overarching neural circuits. One major BPSD domain routinely identified across patients with AD is the Hyperactivity-Impulsivity-Irritiability-Disinhibition-Aggression-Agitation (HIDA) Domain. The HIDA Domain represents one of the most difficult set of symptoms to manage in AD and accounts for much of the burden for caregivers and hospital staff. Although many studies recommend non-pharmacological treatments for HIDA Domain symptoms as first-line, they demonstrate little consensus as to what these treatments should be and are often difficult to implement clinically. Certain symptoms within the HIDA Domain also do not respond adequately to these treatments, putting patients at risk and necessitating adjunct pharmacological intervention. In this review, we summarize the current literature regarding non-pharmacological and pharmacological interventions for the HIDA Domain and provide suggestions for improving treatment. As epigenetic changes due to aging and AD both cause dysfunction in drug-targeted receptors, we propose that HIDA Domain treatments could be enhanced by adjunct strategies that modify these epigenetic alterations and thus increase efficacy and reduce side effects. To improve the implementation of non-pharmacological approaches in clinical settings, we suggest that issues regarding inadequate resources and guidance for implementation should be addressed. Finally, we propose that increased monitoring of symptom and treatment progression via novel sensor technology and the “DICE” (Describe, Investigate, Create, and Evaluate) approach may enhance both pharmacological and non-pharmacological interventions for the HIDA Domain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906 · cited 2×
“…| www.frontiersin.org their use, as is the case for VPA, or is in its infancy, as is the case for AVP-923 (Fhager et al., 2003; Weiner et al., 2005; Birks, 2006; Howard et al., 2007; Kyomen et al., 2007; Ballard et al., 2009; Ng et al., 2009; Rodda et al., 2009; Sommer et al., 2009; Mowla and…”
BackgroundMethodEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Zhao, Q.-F., Tan, L., Wang, H.-F., Jiang, T., Tan, M.-S., Tan, L., Xu, W., Li, J.-Q., Wang, J., Lai, T.-J., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.069 · Cited by 916
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Antidepressant use and risk of adverse outcomes in older people: population based cohort study
Coupland, C., Dhiman, P., Morriss, R., Arthur, A., Barton, G., & Hippisley-Cox, J. (2011) · BMJ · doi:10.1136/bmj.d4551 · Cited by 833
Rolland, Y., Pillard, F., Klapouszczak, A., Reynish, E., Thomas, D., Andrieu, S., Rivière, D., & Vellas, B. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01035.x · Cited by 661
Fractionating impulsivity: neuropsychiatric implications
Dalley, J. W., & Robbins, T. W. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.8 · Cited by 607
Livingston, G., Johnston, K., Katona, C., Paton, J., Lyketsos, C. G., & Old Age Task Force of the World Federation of Biological Psychiatry (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.1996 · Cited by 591
Kales, H. C., Gitlin, L. N., Lyketsos, C. G., & Dementia, T. D. E. P. O. T. A. A. M. O. T. N. S. O. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12730 · Cited by 575
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572
Husebo, B. S., Ballard, C., Sandvik, R., Nilsen, O. B., & Aarsland, D. (2011) · BMJ · doi:10.1136/bmj.d4065 · Cited by 571
Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Chenoweth, L., King, M. T., Jeon, Y.-H., Brodaty, H., Stein-Parbury, J., Norman, R., Haas, M., & Luscombe, G. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70045-6 · Cited by 528
Nobili, A., Latagliata, E. C., Viscomi, M. T., Cavallucci, V., Cutuli, D., Giacovazzo, G., Krashia, P., Rizzo, F. R., Marino, R., Federici, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms14727 · Cited by 514 · cited 1×
“Some degeneration in the mesolimbic dopamine circuitry has also been described and may contribute to these symptoms (Lyness, 2003; Nobili et al., 2017; D’Amelio et al., 2018).”
BackgroundMeta-Analysis of Nonpharmacological Interventions for Neuropsychiatric Symptoms of Dementia
Brodaty, H., & Arasaratnam, C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11101529 · Cited by 479
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Lanctôt, K. L., Amatniek, J., Ancoli‐Israel, S., Arnold, S. E., Ballard, C., Cohen‐Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.07.001 · Cited by 395
Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378
Efficacy of Music Therapy in the Treatment of Behavioral and Psychiatric Symptoms of Dementia
Raglio, A., Bellelli, G., Traficante, D., Gianotti, M., Ubezio, M. C., Villani, D., & Trabucchi, M. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181630b6f · Cited by 333
Treatment of agitation in AD: A randomized, placebo-controlled clinical trial
Teri, L., Logsdon, R. G., Peskind, E., Raskind, M., Weiner, M. F., Tractenberg, R. E., Foster, N. L., Schneider, L. S., Sano, M., Whitehouse, P., et al. (2000) · Neurology · doi:10.1212/wnl.55.9.1271 · Cited by 330
Donepezil for the Treatment of Agitation in Alzheimer's Disease
Howard, R. J., Juszczak, E., Ballard, C. G., Bentham, P., Brown, R. G., Bullock, R., Burns, A. S., Holmes, C., Jacoby, R., Johnson, T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066583 · Cited by 327
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310
Antidepressants for agitation and psychosis in dementia
Seitz, D. P., Adunuri, N., Gill, S. S., Gruneir, A., Herrmann, N., & Rochon, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008191.pub2 · Cited by 304
Neuropsychiatric symptoms in Alzheimer's disease: what might be associated brain circuits?
Rosenberg, P. B., Nowrangi, M. A., & Lyketsos, C. G. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.005 · Cited by 302
Which unmet needs contribute to behavior problems in persons with advanced dementia?
Cohen-Mansfield, J., Dakheel-Ali, M., Marx, M. S., Thein, K., & Regier, N. G. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.03.043 · Cited by 287
Preliminary Findings: Behavioral Worsening on Donepezil in Patients With Frontotemporal Dementia
Mendez, M. F., Shapira, J. S., McMurtray, A., & Licht, E. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000231744.69631.33 · Cited by 267 · cited 1×
“Regarding potentially inefficacious pharmacotherapy for treating disinhibition, one study found that FTD patients treated with donepezil tended to demonstrate increased socially disinhibited behavior, such as inappropriate remarks or unusual interactions with strangers (Mendez et al., 2007).”
BackgroundNeuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis
Lyness, S. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00057-x · Cited by 240 · cited 2×
“…dorsal raphe nucleus and noradrenergic locus coeruleus—are some of the first to degenerate in AD, suggesting that loss of normal function in these regions may underlie some symptoms within the HIDA domain in the early stages of the disease (Parvizi et al., 2001; Lyness, 2003; Šimić et al., 2017).”
BackgroundThe Neurobiology of Impulsive Aggression
Blair, R. J. R. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0088 · Cited by 235
Kales, H. C., Lyketsos, C. G., Miller, E. M., & Ballard, C. (2019) · International Psychogeriatrics · doi:10.1017/s1041610218000534 · Cited by 220
Cummings, J. L., Lyketsos, C. G., Peskind, E. R., Porsteinsson, A. P., Mintzer, J. E., Scharre, D. W., De La Gandara, J. E., Agronin, M., Davis, C. S., Nguyen, U., et al. (2015) · JAMA · doi:10.1001/jama.2015.10214 · Cited by 209
Baker, R., Bell, S., Baker, E., Holloway, J., Pearce, R., Dowling, Z., Thomas, P., Assey, J., & Wareing, L. (2001) · British Journal of Clinical Psychology · doi:10.1348/014466501163508 · Cited by 200
Kolanowski, A., Litaker, M., Buettner, L., Moeller, J., & Costa, Jr. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03449.x · Cited by 199
Calming Music and Hand Massage With Agitated Elderly
Remington, R. (2002) · Nursing Research · doi:10.1097/00006199-200209000-00008 · Cited by 189
Lin, P. W., Chan, W., Ng, B. F., & Lam, L. C. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1688 · Cited by 185
The neurobiological basis of human aggression: A review on genetic and epigenetic mechanisms
Waltes, R., Chiocchetti, A. G., & Freitag, C. M. (2016) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32388 · Cited by 182
Cooke, M. L., Moyle, W., Shum, D. H. K., Harrison, S. D., & Murfield, J. E. (2010) · Aging & Mental Health · doi:10.1080/13607861003713190 · Cited by 177
Sung, H., Lee, W., Li, T., & Watson, R. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2761 · Cited by 174
Bright light therapy for agitation in dementia: a randomized controlled trial
Burns, A., Allen, H., Tomenson, B., Duignan, D., & Byrne, J. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209008886 · Cited by 171
Garland, K., Beer, E., Eppingstall, B., & O'Connor, D. W. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000249388.37080.b4 · Cited by 157
Camberg, L., Woods, P., Ooi, W. L., Hurley, A., Volicer, L., Ashley, J., Odenheimer, G., & McIntyre, K. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb07237.x · Cited by 157
Burns, A., Perry, E., Holmes, C., Francis, P., Morris, J., Howes, M.-J. R., Chazot, P., Lees, G., & Ballard, C. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000324438 · Cited by 149
Management of Neuropsychiatric Symptoms in People with Dementia
Ballard, C., & Corbett, A. (2010) · CNS Drugs · doi:10.2165/11319240-000000000-00000 · Cited by 147
Nonpharmacological intervention for agitation in dementia: A systematic review and meta-analysis
Kong, E.-H., Evans, L. K., & Guevara, J. P. (2009) · Aging & Mental Health · doi:10.1080/13607860902774394 · Cited by 132
Cohen-Mansfield, J., Thein, K., Marx, M. S., Dakheel-Ali, M., & Freedman, L. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07918 · Cited by 129
Konovalov, S., Muralee, S., & Tampi, R. R. (2007) · International Psychogeriatrics · doi:10.1017/s1041610207006540 · Cited by 126
Light Treatment for Neuropsychiatric Behaviors in Alzheimer's Disease
Dowling, G. A., Graf, C. L., Hubbard, E. M., & Luxenberg, J. S. (2007) · Western Journal of Nursing Research · doi:10.1177/0193945907303083 · Cited by 121
Sánchez, A., Maseda, A., Marante-Moar, M. P., de Labra, C., Lorenzo-López, L., & Millán-Calenti, J. C. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-151150 · Cited by 117
Antipsychotic Use in Dementia: Is There a Problem and Are There Solutions?
Kirkham, J., Sherman, C., Velkers, C., Maxwell, C., Gill, S., Rochon, P., & Seitz, D. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716673321 · Cited by 113 · cited 2×
“Despite this lack of clear direction, clinicians routinely prescribe a number of common neuropsychiatric medications, especially for patients in long-term care facilities (Kirkham et al., 2017).”
BackgroundAn Evaluation of a Family Visit Education Program
McCallion, P., Toseland, R. W., & Freeman, K. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb04579.x · Cited by 104
Lowery, D., Cerga‐Pashoja, A., Iliffe, S., Thuné‐Boyle, I., Griffin, M., Lee, J., Bailey, A., Bhattacharya, R., & Warner, J. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4062 · Cited by 102
Imaging of the 5-HT2A system: age-, gender-, and Alzheimer’s disease-related findings
Versijpt, J., Van Laere, K. J., Dumont, F., Decoo, D., Vandecapelle, M., Santens, P., Goethals, I., Audenaert, K., Slegers, G., Dierckx, R. A., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00137-9 · Cited by 102
Non‐pharmacological management of behavioural symptoms in nursing homes
Deudon, A., Maubourguet, N., Gervais, X., Leone, E., Brocker, P., Carcaillon, L., Riff, S., Lavallart, B., & Robert, P. H. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2275 · Cited by 102
Sepehry, A. A., Lee, P. E., Hsiung, G. Y. R., Beattie, B. L., & Jacova, C. (2012) · Drugs & Aging · doi:10.1007/s40266-012-0012-5 · Cited by 94 · cited 1×
“Interestingly, these drugs are notoriously poor for treating affective domain symptoms in AD (Sepehry et al., 2012; Farina et al., 2017), suggesting that their manifestation is unlikely to be similar to that in otherwise healthy, young patients.”
BackgroundManagement of inappropriate sexual behaviors in dementia: a literature review
Tucker, I. (2010) · International Psychogeriatrics · doi:10.1017/s1041610210000189 · Cited by 91 · cited 1×
“Similarly, there have been no RCTs assessing the efficacy of specific pharmacological or non-pharmacological approaches in treating these symptoms in AD (Tucker, 2010; Cipriani et al., 2016).”
BackgroundWoods, P., & Ashley, J. (1995) · Geriatric Nursing · doi:10.1016/s0197-4572(05)80072-2 · Cited by 86
Reducing dangerous nighttime events in persons with dementia by using a nighttime monitoring system
Rowe, M. A., Kelly, A., Horne, C., Lane, S., Campbell, J., Lehman, B., Phipps, C., Keller, M., & Benito, A. P. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.08.005 · Cited by 72
Therapeutic recreation interventions for need-driven dementia-compromised
Fitzsimmons, S., & Buettner, L. L. (2002) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/153331750201700603 · Cited by 64
Behavioural management of aggression in dementia: a randomized controlled trial
Gormley, N. (2001) · Age and Ageing · doi:10.1093/ageing/30.2.141 · Cited by 62
Probable Reasons for Expressed Agitation in Persons with Dementia
Ragneskog, H., Gerdner, L. A., Josefsson, K., & Kihlgren, M. (1998) · Clinical Nursing Research · doi:10.1177/105477389800700207 · Cited by 61
Buettner, L. L., & Fitzsimmons, S. (2002) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/153331750201700205 · Cited by 48 · cited 2×
“…symptoms (Robichaud et al., 1994; Alessi et al., 1999; Baker et al., 2001; Smallwood et al., 2001; Buettner and Fitzsimmons, 2002; Fitzsimmons and Buettner, 2002; Ballard et al., 2002; Holmes et al., 2002; Cott et al., 2002; Remington, 2002; van Diepen et al., 2002; Ancoli-Israel et al., 2003;…”
BackgroundTau phosphorylation in human brain: relationship to behavioral disturbance in dementia
Guadagna, S., Esiri, M. M., Williams, R. J., & Francis, P. T. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.01.015 · Cited by 48
Walking and night-time restlessness in mild-to-moderate dementia: a randomized controlled trial
Eggermont, L. H. P., Blankevoort, C. G., & Scherder, E. J. A. (2010) · Age and Ageing · doi:10.1093/ageing/afq115 · Cited by 39
WANDERING BEHAVIORS in Institutionalized Persons with Dementia
Matteson, M. A., & Linton, A. (1996) · Journal of Gerontological Nursing · doi:10.3928/0098-9134-19960901-11 · Cited by 35 · cited 1×
“As a result of these risks and their impact on caregivers, patients with severe HIDA domain symptoms are more likely than those with other BPSD to be institutionalized and put in restraints (Matteson and Linton, 1996; Gilley et al., 2004).”
BackgroundWeiner, M. F., Tractenberg, R. E., Sano, M., Logsdon, R., Teri, L., Galasko, D., Gamst, A., Thomas, R., & Thal, L. J. (2002) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198870201500208 · Cited by 22
Cited by
Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease
Depp, C., Sun, T., Sasmita, A. O., Spieth, L., Berghoff, S. A., Nazarenko, T., Overhoff, K., Steixner-Kumar, A. A., Subramanian, S., Arinrad, S., et al. (2023) · Nature · doi:10.1038/s41586-023-06120-6 · Cited by 493
Astrocyte calcium dysfunction causes early network hyperactivity in Alzheimer’s disease
Shah, D., Gsell, W., Wahis, J., Luckett, E. S., Jamoulle, T., Vermaercke, B., Preman, P., Moechars, D., Hendrickx, V., Jaspers, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111280 · Cited by 164
Sano, M., Cummings, J., Auer, S., Bergh, S., Fischer, C. E., Gerritsen, D., Grossberg, G., Ismail, Z., Lanctôt, K., Lapid, M. I., et al. (2024) · International Psychogeriatrics · doi:10.1017/s1041610222001041 · Cited by 91
Unsupervised deep learning to detect agitation from videos in people with dementia
Khan, S. S., Mishra, P. K., Javed, N., Ye, B., Newman, K., Mihailidis, A., & Iaboni, A. (2022) · IEEE Access · doi:10.1109/access.2022.3143990 · Cited by 44
Oesterle, D. W., Eckhardt, C. I., & Parrott, D. J. (2023) · Substance Use & Misuse · doi:10.1080/10826084.2023.2247074 · Cited by 4
Metadata
- Authors
- Keszycki, R. M., Fisher, D. W., & Dong, H.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-09-27
- Volume
- 10
- Pages
- 1109-1109
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2970874265
- Cited by
- 73
- References
- 67
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.